ONSERO
DEAD

Serial Number

97238190

Owner

Onsero Therapeutics Inc.

Filing Date

Jan 25, 2022

Add to watchlist:

No watchlists yet
View on USPTO

ONSERO Trademark

Serial Number: 97238190

ONSERO is a trademark filed by Onsero Therapeutics Inc. on January 25, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Onsero Therapeutics Inc.

198 Tremont Street, Suite 143
Boston, MA 02116

Entity Type: 03

Trademark Details

Filing Date

January 25, 2022

Registration Date

Not Registered

Published for Opposition

December 27, 2022

Goods & Services

Pharmaceutical products for the treatment of health and mental health conditions, in particular depression, anxiety, mood disorders, post-traumatic stress disorders, compulsive disorders and migraines; pharmaceutical products for the treatment of health and mental health diseases and disorders in particular depression, anxiety, mood disorders, post-traumatic stress disorders, compulsive disorders and migraines; pharmaceutical products for the treatment of neurological and psychiatric diseases and disorders; diagnostic agents, preparations, and substances for medical purposes; none of the foregoing including pharmaceutical products in the fields of multiple sclerosis, HIV/AIDS, reproductive health, namely, fertility, or oncology, metabolic diseases, or endocrinological diseases

Pharmaceutical and biopharmaceutical research and development; drug discovery services; laboratory research services relating to pharmaceuticals and diagnostics, namely, research in the fields of health and mental health diseases and disorders, neurological diseases and disorders, and psychiatric diseases and disorders; provision of information and data relating to medical research and development in the fields of health and mental health diseases and disorders, neurological diseases and disorders, and psychiatric diseases and disorders; consultancy in the field of pharmaceutical and pharmaceutical diagnostics research; none of the foregoing including pharmaceutical products in the fields of multiple sclerosis, HIV/AIDS, reproductive health, namely, fertility, or oncology, metabolic diseases, or endocrinological diseases

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Mar 4, 2024 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Mar 4, 2024 ABN6
WITHDRAWAL OF ATTORNEY GRANTED
Nov 19, 2023 WOAG
TEAS WITHDRAWAL OF ATTORNEY RECEIVED
Nov 19, 2023 WOAR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 17, 2023 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Nov 17, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Nov 17, 2023 COAR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 1, 2023 NOAM
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Jun 21, 2023 ETOP
POST PUBLICATION AMENDMENT - ENTERED
Jun 6, 2023 CHPB
ASSIGNED TO PETITION STAFF
Jun 5, 2023 APET
TEAS POST PUBLICATION AMENDMENT RECEIVED
May 15, 2023 EPPA
EXTENSION OF TIME TO OPPOSE RECEIVED
Jan 16, 2023 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 27, 2022 NPUB
PUBLISHED FOR OPPOSITION
Dec 27, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 7, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 19, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 18, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 18, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 18, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 15, 2022 GNRN
NON-FINAL ACTION E-MAILED
Nov 15, 2022 GNRT
NON-FINAL ACTION WRITTEN
Nov 15, 2022 CNRT
ASSIGNED TO EXAMINER
Nov 3, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 31, 2022 NWOS
NEW APPLICATION ENTERED
Jan 28, 2022 NWAP